|
|
Blood, 15 October 2004, Vol. 104, No. 8, pp. 2591-2599.
Prepublished online as a Blood First Edition Paper on July 1, 2004; DOI 10.1182/blood-2004-02-0459.
Previous Article | Next Article 
Submitted February 9, 2004
Accepted June 14, 2004
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA-class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression
Andreas Doerrschuck, Andrea Schmidt, Elke Schnuerer, Matthias Glueckmann, Christian Albrecht, Catherine Woelfel, Volker Lennerz, Alexander Lifke, Carmela Di Natale, Elena Ranieri, Loreto Gesualdo, Christoph Huber, Michael Karas, Thomas Woelfel, and Wolfgang Herr*
Department of Medicine III, Johannes Gutenberg-University of Mainz, Mainz, Germany
Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-University of Frankfurt, Frankfurt, Germany
Applied Biosystems, Darmstadt, Germany
Department of Nephrology, University of Bari, Bari, Italy
* Corresponding author; email: w.herr{at}3-med.klinik.uni-mainz.de.
Allogeneic hematopoietic stem-cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8+ T-cell responses in blood lymphocytes of healthy individuals matched with established RCC-cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTC), RCC-reactive cytotoxic T-lymphocytes (CTL) were readily obtained. From MLTC, 121 CD8+ CTL clones with memory phenotype were isolated. Their anti-RCC-reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, -A3, -B7, -B44, -Cw7, and by a nonclassical HLA-Ib determinant. Extensive cross-reactivity analyses on a broad target panel identified CTL recognizing antigens with expression restricted to renal tissue or to renal and colon tumors. Other CTL were directed against antigens with broader tissue distribution being expressed in various epithelial and nonepithelial tumors or, additionally, in hematopoietic cells. With microcapillary LC and MALDI-TOF/TOF mass spectrometry, we identified the HLA-A*0301-associated nonpolymorphic peptide KLPNSVLGR encoded by the ubiquitously expressed Eps15 homology-domain containing-2 gene as a CTL target. Defining human RCC antigens recognized by alloreactive CTL may allow to improve the specificity and efficiency of allogeneic cell therapy (e.g. specific donor-lymphocyte infusions or vaccination) in metastatic RCC patients.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt
A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors
Haematologica,
February 1, 2008;
93(2):
265 - 272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Atreya, C. C Schimanski, C. Becker, S. Wirtz, H. Dornhoff, E. Schnurer, M. R Berger, P. R Galle, W. Herr, and M. F Neurath
The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer
Gut,
November 1, 2007;
56(11):
1572 - 1578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al.
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Blood,
January 1, 2007;
109(1):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Meyer, C. M. Britten, D. Wehler, K. Bender, G. Hess, A. Konur, U. F. Hartwig, T. C. Wehler, A. J. Ullmann, C. Gentilini, et al.
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation
Blood,
January 1, 2007;
109(1):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al.
Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
Cancer Res.,
December 1, 2006;
66(23):
11447 - 11454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hofmann, M. Gluckmann, S. Kausche, A. Schmidt, C. Corvey, R. Lichtenfels, C. Huber, C. Albrecht, M. Karas, and W. Herr
Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS
Mol. Cell. Proteomics,
December 1, 2005;
4(12):
1888 - 1897.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |